MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$18,868,885
EPS
-$0.35
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue
-0* --
Research and development
13,397,977 10,402,327* 8,970,010 6,996,660
General and administrative
6,599,759 4,934,491* 3,708,959 2,735,401
Total operating expenses
19,997,736 15,336,818* 12,678,969 9,732,061
Loss from operations
-19,997,736 -15,336,818* -12,678,969 -9,732,061
Changes in fair value of warrant liabilities
482,474 24,822,933* -61,598,908 627,056
Interest expense
62,745 79,208.5* 43,292 64,345
Interest income
1,047,197 428,839.5* 655,233 13,562
Other income
626,873 1,541,517.5* 765,881 295,630
Warrant issuance cost
--4,852,292 -
Warrant issuance expense
-1,213,073* --
Total other income
1,128,851 -24,144,857.5* 58,124,438 -382,209
Net gain
-18,868,885 -39,481,675.5* 45,445,469 -10,114,270
Unrealized gain, change in fair value of available-for-sale securities, net of tax
-46,366* --
Foreign currency translation gain (loss)
-34,114* --
Total comprehensive income (loss)
--39,401,195.5 --
Basic EPS
-0.35 -1.037 0.5 -1.09
Diluted EPS
-0.35 -0.642 -0.21 -1.09
Basic Average Shares
53,558,639 37,980,425 10,660,500 9,294,469
Diluted Average Shares
53,558,639 61,340,193* 77,863,263 9,294,469
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$1,047,197 Other income$626,873 Net gain-$18,868,885 Total other income$1,128,851 Changes in fair value ofwarrant liabilities$482,474 Interest expense$62,745 Loss from operations-$19,997,736 Total operatingexpenses$19,997,736 Research and development$13,397,977 General andadministrative$6,599,759

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. (SABS)